Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.39 |
| ▸ | FABP3 | P05413 | 4/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 3/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633424 | 0.86 | SMN1; SMN2 (0.37) | FABP3DGAT1PPARDPPARANPC1 | |
| SCHEMBL6034853 | 0.84 | PPARD (0.42) | FABP3DGAT1PPARDPPARA | |
| SCHEMBL6035372 | 0.84 | PPARD (0.36) | DGAT1PPARDPPARANPC1RAB9A | |
| SCHEMBL6035388 | 0.82 | SMN1; SMN2 (0.37) | DGAT1PPARDPPARANPC1RAB9A | |
| SCHEMBL6035915 | 0.80 | PPARG (0.40) | ALDH1A1FFAR4DGAT1PPARDPPARA | |
| SCHEMBL6036309 | 0.79 | FFAR4 (0.47) | ALDH1A1FFAR4PPARANPC1RAB9A | |
| SCHEMBL6035191 | 0.79 | MRGPRX4 (0.35) | FFAR4FABP3PPARDPPARA | |
| SCHEMBL5120333 | 0.78 | PPARG (0.47) | FABP3FABP4SNCA | |
| SCHEMBL6216247 | 0.78 | HTT (0.37) | FABP3FABP4NPC1RAB9ASNCA | |
| SCHEMBL6036223 | 0.76 | PLA2G4B (0.43) | ALDH1A1PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | ALDH1A1 1442/4885FFAR4 195/4885FABP3 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.